NASDAQ:TVGN Tevogen Bio (TVGN) Stock Price, News & Analysis $1.07 -0.02 (-1.83%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$1.08 +0.00 (+0.47%) As of 07:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tevogen Bio Stock (NASDAQ:TVGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tevogen Bio alerts:Sign Up Key Stats Today's Range$1.04▼$1.1150-Day Range$1.06▼$1.6852-Week Range$0.26▼$4.78Volume162,660 shsAverage Volume5.06 million shsMarket Capitalization$187.30 millionP/E RatioN/ADividend YieldN/APrice Target$7.10Consensus RatingBuy Company OverviewTevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.Read More… Remove Ads Tevogen Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreTVGN MarketRank™: Tevogen Bio scored higher than 63% of companies evaluated by MarketBeat, and ranked 366th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTevogen Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTevogen Bio has only been the subject of 1 research reports in the past 90 days.Read more about Tevogen Bio's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.47% of the float of Tevogen Bio has been sold short.Short Interest Ratio / Days to CoverTevogen Bio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tevogen Bio has recently increased by 7.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTevogen Bio does not currently pay a dividend.Dividend GrowthTevogen Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.47% of the float of Tevogen Bio has been sold short.Short Interest Ratio / Days to CoverTevogen Bio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tevogen Bio has recently increased by 7.69%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News SentimentN/A News SentimentTevogen Bio has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Tevogen Bio this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for TVGN on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows2 people have added Tevogen Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tevogen Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $446,762.00 in company stock.Percentage Held by Insiders56.60% of the stock of Tevogen Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Tevogen Bio's insider trading history. Receive TVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tevogen Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TVGN Stock News HeadlinesTevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Neal Flomenberg Sells 232,968 SharesMarch 15, 2025 | insidertrades.comTevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells $76,718.56 in StockMarch 12, 2025 | insidertrades.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.April 3, 2025 | Brownstone Research (Ad)Insider Selling: Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells 14,639 Shares of StockMarch 7, 2025 | insidertrades.comTevogen Bio appoints new head of government affairsMarch 27, 2025 | uk.investing.comTevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced ForecastMarch 26, 2025 | globenewswire.comTevogen Bio benoemt nieuwe directeur overheidsrelatiesMarch 26, 2025 | nl.investing.comTevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization PlanMarch 25, 2025 | globenewswire.comSee More Headlines TVGN Stock Analysis - Frequently Asked Questions How have TVGN shares performed this year? Tevogen Bio's stock was trading at $1.03 at the beginning of 2025. Since then, TVGN stock has increased by 3.9% and is now trading at $1.07. View the best growth stocks for 2025 here. How do I buy shares of Tevogen Bio? Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tevogen Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tevogen Bio investors own include NVIDIA (NVDA), Candel Therapeutics (CADL), CXApp (CXAI), GlycoMimetics (GLYC), Rigetti Computing (RGTI), XTI Aerospace (XTIA) and Aldeyra Therapeutics (ALDX). Company Calendar Today4/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TVGN Previous SymbolNASDAQ:TVGN CIK1860871 Webwww.semperparatusspac.com Phone913-579-4170FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$7.10 High Stock Price Target$10.00 Low Stock Price Target$4.20 Potential Upside/Downside+563.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-396.07% Return on Assets749.97% Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick Ratio0.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.10) per share Price / Book-0.97Miscellaneous Outstanding Shares175,051,000Free Float75,972,000Market Cap$187.30 million OptionableN/A Beta-1.07 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:TVGN) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.